Drug repurposing in the treatment of COVID-19: A review


  • S. Gadge Sonali P. R. Patil Institute of Pharmacy, Talegaon (SP), Wardha, Maharashtra?442202, India
  • L. Salode Vikrant P. R. Patil Institute of Pharmacy, Talegaon (SP), Wardha, Maharashtra?442202, India
  • D. Game Madhuri Vidyabharati College of Pharmacy, C.K. Naidu Road, Amravati, Maharashtra?442202, India




COVID-19, SARS-CoV-2, Drug Repurposing, Remdesivir, Chloroquine and hydroxychloroquine.


The first outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection was in Wuhan, Hubei, China in December 2019 and declared as a pandemic by the World Health Organization. Currently, there is no proven effective vaccine or therapeutic agent to combat the deadly coronavirus disease. Currently, prevention from the infection, control measures and supportive care help to treat against COVID-19. Until an effective vaccine is available for COVID-19 infection, one can repurpose known therapeutic agents that block the entry of the virus into the host cell and control the COVID-19 infection. Drug repurposing is the new use of old drugs. In this review, the most common and possible drug treatment for COVID-19 is highlighted. The therapeutic agents include antiviral drugs like Remdesivir, chloroquine, hydroxychloroquine, lopinavir/ritonavir, umifenovir, favipiravir and oseltamivir and other agents. Clinical trials are ongoing to evaluate the safety and efficacy of these therapeutic agents in COVID-19 patients.


Download data is not yet available.



How to Cite

Sonali, S. G., L. S. Vikrant, and D. G. Madhuri. “Drug Repurposing in the Treatment of COVID-19: A Review”. Research in Pharmacy, vol. 11, Mar. 2021, pp. 1-7, doi:10.25081/rip.2021.v11.6611.